Artelus is the Bengaluru-based company behind DRISTi AI, a deep learning based AI algorithm that reads digital images to detect early signs of diabetic retinopathy, and it is now drawing attention from doctors across India. At AIOC 2026 in Jaipur, one of India's biggest ophthalmology conferences, we asked ophthalmologists to share their experience with Artelus's EZZEntial™ OCT, DRISTi AI and AI-enabled fundus imaging solution, and recorded their answers on camera.
Ten doctors, from young practitioners to senior vitreo-retina surgeons, praised the same things: image quality, portability, affordability, and ease of use. Watch each video below, or read the highlights.
For a retinal imaging device, the image is everything, and it was the first thing doctors mentioned.
Dr. Shubhrat Misuriya said Artelus "strikes the perfect balance between exceptional imaging quality and strong return on investment for clinics." He added: "The clarity and reliability of the images support confident clinical decisions."
Dr. L.C. Madharia said the EZZEntial™ OCT "delivers impressive imaging quality and shows strong potential in advancing retinal care, including ROP." He called it "a highly effective solution," rating its overall performance 9 out of 10.
Dr. Varun Gogia pointed to "the cutting-edge technology that consistently delivers high-quality retinal images."
Dr. D. P. Prakash said the Artelus fundus imaging solution "stands out for its exceptional image quality and powerful AI integration." In his words: "The high-quality retinal images, combined with advanced AI-enabled innovation, make it a truly impactful tool in clinical practice."
Portability was the most repeated theme. Doctors described devices that work outside the big hospital, in the clinics and camps where screening is needed most.
Dr. Bhavit: "The Artelus EZZEntial™ OCT is ideally suited for rural clinics, thanks to its portability and cost-effectiveness. Despite its compact design, it consistently delivers high-quality retinal images, making advanced eye care more accessible without compromising on performance."
Dr. Gajendra Chawla, Senior Vitreo-Retina Surgeon, called portability and affordable pricing the key USPs, "making it highly accessible across diverse clinical settings." He added that "the fast imaging speed and consistently high-quality retinal outputs further strengthen its value, enabling efficient workflows without compromising on diagnostic accuracy."
Several doctors described Artelus as strong value for money, and a good fit for practices at an early stage.
Dr. Sneha: "The Artelus EZZEntial™ OCT comes highly recommended for young ophthalmologists starting their practice. Its reasonable pricing, portability, and quick, efficient operation make it a practical choice for everyday use. The AI-integrated reports and high-quality imaging further enhance its clinical value, making it a smart investment that seamlessly blends advanced technology with real-world usability."
Dr. Rajiv Brahmane: "The Artelus EZZEntial™ OCT & Fundus solutions stand out for their portability and ease of use. They consistently deliver high-quality retinal imaging, while offering exceptional value for money, making them a reliable and practical choice for everyday clinical practice."
Dr. Krithika: "The Artelus EZZEntial™ OCT seamlessly combines portability, ease of use, and excellent retinal imaging. It's a practical solution that fits effortlessly into real-world clinical settings, supporting efficient workflows and reliable patient care."
Dr. Chinmayee Melvanki said: "The quality and clarity of Artelus products are truly impressive. It's encouraging to see such high standards being achieved, and it underscores the importance of supporting Indian-made innovations."
The doctors at AIOC 2026 made their views clear. To learn more about DRISTi AI, the EZZEntial™ OCT, and Artelus's AI-enabled fundus imaging solution, or to request a demo, visit www.artelus.com or contact@artelus.com
Diabetic retinopathy continues to be one of the leading causes of preventable blindness in India, and access to timely retinal screening remains the ...
Detecting Glaucoma Through AI: Advancing Early Diagnosis and Preventing Vision LossLeveraging Artificial Intelligence for Automated Optic Nerve Ana...
Artificial Intelligence is Transforming Diabetic Retinopathy Detection with Faster, More Accurate, and Accessible Retinal ScreeningDiabetic retinopat...
What Pending FDA Approval Means for AI in Healthcare: Why It Matters for India's Medical Device IndustryArtificial Intelligence (AI) is rapidly trans...
Key Highlights Artificial Intelligence and deep learning have revolutionized the field of ophthalmology by improving disease detection and diagnosis....
IntroductionArtificial Intelligence (AI) in Healthcare has already been used in radiology and drug discovery. However, many other healthcare areas co...
AI technology assists in diagnosing diabetic retinopathy.AI technology can assist in diagnosing diabetic retinopathy by analyzing retinal images for ...
Key Highlights AI is revolutionizing the healthcare industry, with the AI healthcare market projected to be worth $187 billion by 2030. AI technolog...
# From Pandemic to Endemic - The new NormalFor a world grappling with the new coronavirus, it’s becoming increasingly clear that even when the pandem...
AI-Powered Retinal Screening: Transforming Eye Care for the Forgotten Billions Retinal diseases such as diabetic retinopathy and other sight-threateni...
The foundational ethos of Artelus is encapsulated in its forward-thinking vision: Leveraging state-of-the-art Deep Learning architectures to democratize healthcare for the "Forgotten Billions". At Artelus.ai, we are dedicated to advancing eye care through innovative technology and comprehensive solutions, making high-quality diagnostics accessible to all. Join us in revolutionizing healthcare and improving the lives of millions around the world.